Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with <it>trypanosoma cruzi</it> antigens
<p>Abstract</p> <p>Background</p> <p>Benznidazole (Bz)-chemotherapy is recommended to prevent Chagas disease progression, despite its limited efficacy during chronic disease. However, the host mechanisms underlying these benefits still remain to be elucidated.</p>...
Main Authors: | Sathler-Avelar Renato, Vitelli-Avelar Danielle, Elói-Santos Silvana, Gontijo Eliane, Teixeira-Carvalho Andréa, Martins-Filho Olindo |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-05-01
|
Series: | BMC Infectious Diseases |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1471-2334/12/123 |
Similar Items
-
Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease
by: Margoth Moreno, et al.
Published: (2010-11-01) -
Transcriptomic analysis of benznidazole-resistant and susceptible Trypanosoma cruzi populations
by: Davi Alvarenga Lima, et al.
Published: (2023-05-01) -
Modulation of Trypanosoma cruzi-specific T-cell responses after chemotherapy for chronic Chagas disease
by: María Cecilia Albareda, et al.
Published: (2015-05-01) -
Enfermedad de Chagas aguda, en un adulto tratado con benznidazol (Rochagan®) en Costa Rica
by: Víctor M. Montenegro, et al.
Published: (2004-06-01) -
Enfermedad de Chagas aguda, en un adulto tratado con benznidazol (Rochagan®) en Costa Rica
by: Víctor M. Montenegro, et al.
Published: (2004-06-01)